Jennifer Barrett, Associate Editor

The FDA does not usually require animalstudies for biosimilars; therefore, the process can move directly to pharmacokinetic and pharmacodynamic studies.

According to the experts, having well thought-out administration procedures is imperative to providing a smooth transition process for the health care team.

The phase 3b/4 SPIRIT head-to-head study evaluated ixekizumab (Taltz) versus adalimumab (Humira) in psoriatic arthritis.

Approved by the FDA in May 2019, midazolam nasal spray CIV (Nayzilam, UCB) is the first nasal rescue treatment for seizure clusters in the United States.

The study evaluated the safety and efficacy of a live, attenuated zoster vaccine patients receiving tumor necrosis factor inhibitor therapies for various indications.

Under a new international collaboration, the FDA has granted supplemental approval to acalabrutinib (Calquence, AstraZeneca) for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic leukemia.

The COAST-X study evaluated ixekizumab (Taltz, Eli Lilly) in patients with non-radiographic axial spondyloarthritis.

With vincristine in short supply, Teva will resume production of the chemotherapy agent following its previous decision to remove the product from the market.

Findings from a phase 3 study reinforced the safety and efficacy of rituximab (Rituxan, Genentech) as a treatment for patients with pemphigus vulgaris.

The Ensuring Seniors Access to Local Pharmacies Act, which was recently reintroduced, would allow more “preferred” pharmacies in medically underserved areas.

The FDA Drug Shortages Task Force addressed the root causes of drug shortages and proposed potential solutions.

In today's evolving health care and reimbursement landscape, specialty pharmacies are facing pressure to adopt more efficient and cost-effective solutions.

Dupixent is the first FDA-approved medicine for adults with chronic rhinosinusitis with nasal polyposis and the only approved therapy shown to shrink nasal polyp size and improve the signs and symptoms of the associated chronic rhinosinusitis.

Limited supply of chemotherapy agent that treats several pediatric cancers may lead to rationing of doses.

Specialty pharmacists a crucial role in optimizing the treatment of patients with inflammatory diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS).

In an ever-changing regulatory health care landscape, specialty pharmacies must continuously ensure they are adapting to evolving industry standards.

More than a year after the Trump administration’s drug pricing blueprint was released, reform has remained at the forefront of many discussions involving health care legislation.

For many Americans living in today’s health care environment, cost is a dominant concern when a serious disease is diagnosed.

The International Society of Oncology Pharmacy Practitioners global position on oncology biosimilar use covers regulation and evaluation, implementation, education, and monitoring.

New study provides evidence that the use of antiretroviral therapy alters the formation or stabilization of HIV latent reservoirs.

Long-term treatment with dupilumab showed benefit in adolescents with atopic dermatitis comparable with the treatment’s effect in adults.

A session at the ESMO Congress 2019 highlighted potential prevention and treatment strategies for life-threatening immunotherapy toxicities in patients with cancer.

Patients with diabetes demonstrated a higher likelihood of developing non-Hodgkin lymphoma than those without diabetes, especially among men.

Despite advances in cancer care, patients typically face obstacles to treatment.

Research demonstrates a new direction in cell signaling and treatment for chronic inflammatory diseases such as psoriasis, asthma, and HIV.

ABP 798, a biosimilar candidate to rituximab (Rituxan), demonstrated clinical equivalence in a study of patients with non-Hodgkin lymphoma.

An upcoming webinar by Trellis Rx on Wednesday, September 18, will offer a firsthand look into how to accelerate the growth of your specialty pharmacy program by building strong provider partnerships.

In an ideal world, how would you hypothesize that technology might be able to solve all of your problems?

With rapid growth, health system specialty pharmacies are more than likely to run into several operational pain points.

With specialty pharmacy emerging as the fastest growing segment of the pharmacy industry, health systems have to address a key question: can you scale for it?